Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Sensitive Mutation”

45 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 45 results

Early research (Phase 1)Study completedNCT00903734
What this trial is testing

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Who this might be right for
Advanced Cancers
M.D. Anderson Cancer Center 16
Post-approval studies (Phase 4)UnknownNCT04132102
What this trial is testing

To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation

Who this might be right for
Lung Squamous Cell Carcinoma
Shanghai Chest Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT05284539
What this trial is testing

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 760
Testing effectiveness (Phase 2)UnknownNCT02098954
What this trial is testing

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Who this might be right for
Carcinoma, Non-Small Cell LungEGFR Gene Mutation
Hunan Province Tumor Hospital 40
Early research (Phase 1)Study completedNCT02926768
What this trial is testing

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungLung Diseases+1 more
Checkpoint Therapeutics, Inc. 136
Large-scale testing (Phase 3)Active Not RecruitingNCT04687241
What this trial is testing

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 192
Large-scale testing (Phase 3)Looking for participantsNCT06735391
What this trial is testing

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Who this might be right for
Locally Advanced or Metastatic Non-squamous NSCLCHarboring EGFR Sensitive Mutations NSCLCPreviously Untreated Systematically NSCLC
Shanghai JMT-Bio Inc. 516
Not applicableUnknownNCT02803619
What this trial is testing

A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis

Who this might be right for
Non-small Cell Lung CancerLeptomeningeal Metastasis
Peking Union Medical College Hospital 60
Not applicableStudy completedNCT02148380
What this trial is testing

Combination of Chemotherapy and Gefitinib as First-line Treatment

Who this might be right for
Non-Small-Cell Lung Cancer
Baohui Han 121
Large-scale testing (Phase 3)Looking for participantsNCT06041776
What this trial is testing

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Who this might be right for
Non-Small Cell Lung CancerEGFR Sensitive MutationAdjuvant Therapy
Betta Pharmaceuticals Co., Ltd. 570
Testing effectiveness (Phase 2)UnknownNCT02951637
What this trial is testing

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Who this might be right for
Lung Adenocarcinoma
Shanghai Chest Hospital 300
Testing effectiveness (Phase 2)Study completedNCT01922583
What this trial is testing

AUY922 in Patient With Stage IV NSCLC

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
National Taiwan University Hospital 31
Testing effectiveness (Phase 2)Study completedNCT01802632
What this trial is testing

AZD9291 First Time In Patients Ascending Dose Study

Who this might be right for
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
AstraZeneca 603
Testing effectiveness (Phase 2)Looking for participantsNCT06709859
What this trial is testing

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Shandong Public Health Clinical Center 30
Testing effectiveness (Phase 2)UnknownNCT03396185
What this trial is testing

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Who this might be right for
EGFR Gene MutationNon Small Cell Lung Cancer Stage IIIANon Small Cell Lung Cancer Stage IIIB
Betta Pharmaceuticals Co., Ltd. 30
Large-scale testing (Phase 3)Active Not RecruitingNCT03787992
What this trial is testing

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 358
Testing effectiveness (Phase 2)UnknownNCT03457337
What this trial is testing

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Who this might be right for
Advanced NSCLC With EGFR Mutation
Henan Cancer Hospital 200
Large-scale testing (Phase 3)Not Yet RecruitingNCT07416994
What this trial is testing

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. 440
Testing effectiveness (Phase 2)Looking for participantsNCT07505173
What this trial is testing

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

Who this might be right for
Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital 74
Large-scale testing (Phase 3)Looking for participantsNCT06043973
What this trial is testing

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Who this might be right for
Advanced Non-small Cell Lung Cancer
Qianfoshan Hospital 98
Load More Results